Document |
Document Title |
WO/2024/030976A2 |
The disclosure relates to compositions and methods for the preparation, use, and/or formulation of active agents conjugated to ligands for increased crossing of the blood brain barrier.
|
WO/2024/031008A2 |
siRNA molecules targeting AGT mRNA that reduce or inhibit AGT production are provided. Pharmaceutical compositions containing such siRNA molecules also are provided, together with methods of their use for treating hypertension. Pharmaceu...
|
WO/2023/235232A2 |
Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. ...
|
WO/2023/209186A1 |
The present disclosure relates to peptide fragments derived from interleukin-4 (IL-4) for the treatment of diabetic nephropathy.
|
WO/2023/205642A2 |
Disclosed herein are methods and systems for engineering glycosylation. The methods and systems may use structure of sequence information of biomolecules to predict glycosylation features. The methods and systems may employ one or more t...
|
WO/2023/178421A1 |
The present document describes antibodies or antigen-binding fragments that bind specifically to a target antigen, wherein the antibodies or antigen-binding fragments comprise complementarity determining regions (CDR1, CDR2 and CDR3) and...
|
WO/2023/161962A1 |
The present invention relates to Muramyl dipeptide compounds having adjuvant activity. The present invention also discloses the process for the preparation of Muramyl dipeptide compound and their intermediates. The immuno-modulating prop...
|
WO/2023/141855A1 |
Provided herein is a protein conjugate with multiple payloads and methods for making the same.
|
WO/2023/143374A1 |
The present invention relates to a ligand, a method for preparing same, and a use thereof. The ligand has a structure represented by formula (I) or formula (II), wherein R1, R2, R3, and R4 are all linear structures with a glycosyl group ...
|
WO/2023/121483A1 |
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator...
|
WO/2023/097374A1 |
Provided herein are metal-organic framework (MOF) biocomposites, in particular biocomposites comprising partially embedded biomolecules such as antibodies. Also provided herein are methods of producing the MOF biocomposites, and uses of ...
|
WO/2023/077447A1 |
Disclosed are a cyclopeptide glass and a pharmaceutical composition glass containing a cyclopeptide. The cyclopeptide glass of the present invention can simultaneously exert efficacy and a drug adjuvant function. Compared with crystals a...
|
WO/2023/065137A1 |
The present disclosure provides a protein conjugate, comprising a protein and an oligosaccharide, wherein the oligosaccharide comprises Formula (1) : wherein, the GlcNAc is directly or indirectly linked to an amino acid of the protein, t...
|
WO/2023/058527A1 |
A compound represented by formula (1) [in formula (1): Xaa, Xaa1, Xaa2 and Xaa3 independently represent an arbitrary amino acid residue; n represents an integer of 1-20; R is nil or represents a straight-chain or branched sugar chain con...
|
WO/2023/023031A2 |
Described herein are peptide oligonucleotide complexes comprising peptides and variants thereof as well as conjugated to, linked to, or fused to agents, wherein the peptide oligonucleotide complexes are capable of binding TfR and that ar...
|
WO/2022/268939A1 |
The present invention relates to peptides, their use in the treatment, amelioration or prevention of chronically active autoimmune inflammation, in particular rheumatoid arthritis, and to pharmaceutical compositions comprising the same.
|
WO/2022/266758A1 |
Provided herein are compounds including a linear polyglycerol, a peptide tag, with either a linker-sugar-sialic acid moiety or a sulfate group, a preservation solutions including the compounds, methods for using the compounds or the pres...
|
WO/2022/270482A1 |
The present invention provides: sugar chain immobilized polymer particles in which a hydrophobized sugar chain polypeptide is firmly immobilized to the outermost surface of the polymer particles and the sugar chain density on the surface...
|
WO/2022/255289A1 |
The present invention relates to a method for producing a glycopeptide, the method including a step for modifying an Fc region of an avian antibody, and a step for lysing the modified Fc region using a proteolytic enzyme, and the glycope...
|
WO/2022/245553A2 |
The present invention is related to the field of pulmonary therapeutics. In particular, the compositions described herein are used in methods of treating lung disease and injury including but not limited to acute respiratory distress syn...
|
WO/2022/226083A1 |
Disclosed herein are glycan-coated RBD immunogens, engineered nanoparticle vaccines comprising glycan-coated RBD immunogens and methods of use thereof for SARS-CoV-2 vaccines.
|
WO/2022/224015A1 |
An improved method for the chemical synthesis of glycosylated peptides has been developed. The method uses stereoselective glycan synthesis and chemical peptide ligation to produce glycopeptides at lower-cost and with higher efficiency/y...
|
WO/2022/177913A1 |
This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a mesothelin polypeptide. For example, binders (e.g., antibodies, ...
|
WO/2022/150924A1 |
Carbohydrate of Formula (A) where R1 is H and n an integer from 1 to 5, is synthesized by reacting, under heating, compound (A0) with HO-(CH2)n-CH=CH2 in the presence of an acid capable of liberating a proton, and cooling the reaction mi...
|
WO/2022/155289A1 |
This disclosure relates to PEGylated selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide...
|
WO/2022/148816A1 |
This invention relates to the inhibition of the proliferation and/or activation of T cells by full-length factor V (FV) protein and peptides derived from full-length FV protein. This may be used to exert an immunosuppressive effect in th...
|
WO/2022/148868A1 |
An optimized method for synthesizing dalbavancin is provided in which an organic antisolvent such as tert-butyl methyl ether (TBME) or dimethoxyethane (DME) is used to precipitate the product of the esterification of A-40926.
|
WO/2022/119917A1 |
The present invention provides compositions and methods useful in the diagnosis and treatment of a variety of cognitive impairments including vascular cognitive impairment and dementia, and Alzheimer's Disease. In one particular embodime...
|
WO/2022/109327A1 |
Methods for measuring disialylated Fc glycan in a biological sample are described.
|
WO/2022/093684A1 |
It has been discovered that phosphorylation-dependent uncoupling of endothelial nitric oxide synthase (eNOS) plays an important role in endothelial cell (EC) barrier disruption. Compositions and methods to reduce or prevent eNOS uncoupli...
|
WO/2022/037665A1 |
The present disclosure provides a site-specific protein conjugate and the method for preparation of the same. The protein conjugate comprising a protein and an oligosaccharide, wherein said oligosaccharide comprises (I) wherein: said Glc...
|
WO/2021/228853A1 |
The present invention relates to a vaccine composition and its use against a Severe acute respiratory syndrome-related coronavirus.
|
WO/2021/216323A1 |
A series of vancomycin C-terminus guanidine modifications are disclosed that improve antimicrobial activity, enhance the durability of antimicrobial action against selection or induction of resistance, and provide two synergistic mechani...
|
WO/2021/202208A1 |
Embodiments of methods are disclosed for inhibiting, regulating and/or otherwise affecting or managing the pri-miR- 17-92 cluster, and certain pre-miRNA's embedded in the cluster as well as the pre-miRNA's themselves as isolated forms, a...
|
WO/2021/202621A2 |
The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which c...
|
WO/2021/179081A1 |
The present document describes methods of using a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I ...
|
WO/2021/153687A1 |
Disclosed is a nucleic acid complex represented by formula (I) or a pharmaceutically acceptable salt thereof (X is CH2 or O; Y is a sugar ligand having mannose or GalNac; n is an integer of 1 to 8; and Z is a group containing an oligonuc...
|
WO/2021/146812A1 |
The present document describes uses and methods of using a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general f...
|
WO/2021/084552A1 |
The present invention relates to liposomally bound novel peptide fragments complexed with one or more TLR1/2 and TLR9 ligands useful as vaccine against tuberculosis and for enhancing BCG vaccine efficacy upon concomitant use.
|
WO/2021/081420A2 |
Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic m...
|
WO/2021/068080A1 |
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: - KQPAa; QPAKa; PAKQa; or AKQPa; - NPDPb; PNPDb; DPNPb; or P...
|
WO/2021/067741A1 |
The present disclosure describes a CD4+ T cell repertoire that recognizes a glycopeptide epitope on gp120 presented by a MHCII pathway. The present disclosure provides gp120 glycopeptides that are capable of inducing specific humoral and...
|
WO/2021/056098A1 |
Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier pro...
|
WO/2021/060980A1 |
Provided herein are lipidated glycopeptide compounds of formula (I); or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof. R1 is a lipid, R2 is -H or a lipid, and R3 and R4 are as defined herein. These compoun...
|
WO/2021/046139A1 |
Methods for analysis of a glucuronide ligand-drug conjugate are provided.
|
WO/2020/229982A1 |
The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in...
|
WO/2020/222100A1 |
Method for purifying at least one lipoglycopeptide antibiotic comprising the steps of: i) dissolving said at least one lipoglycopeptide antibiotic in an aqueous solution to form a mixture, ii) loading said mixture into a chromatographic ...
|
WO/2020/182203A1 |
Disclosed is a separation and purification method for a vancomycin analogue (I). The method comprises: using a vancomycin crude product as a raw material, firstly using polymer matrix chromatography packing for enrichment, and then perfo...
|
WO/2020/176921A1 |
The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the prepara...
|
WO/2020/159389A1 |
The subject of the invention comprises new compounds forming Van-TPlO conjugates, method of their preparation, composition and use in antibacterial treatment against Staphylococcus aureus, Enterococcus spp. and Neisseria spp.
|